Loading
A phase 3 trial of Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Dinutuximab, Cisplatin and Irinotecan in High-risk neuroblastoma, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) is a phase 3 interventional study registered as NCT04221035 by Gustave Roussy, Cancer Campus, Grand Paris, with 800 participants planned, started 2019-11-05 and due to reach its primary completion in 2026-11. Interventions recorded: Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Radiotherapy, Dinutuximab Beta, Cisplatin, Temozolomide 100 MG, Irinotecan, Cyclophosphamid. Conditions recorded: High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy.
Linked to the drug Vindesine because the registry names it among its interventions and High-risk neuroblastoma among its conditions. Registry record only: no result has been read by an editor.
Shares Vindesine, Ifosfamide, Vincristine, Etoposide and the tag pipeline.
Shares Vindesine, Ifosfamide, Vincristine, Etoposide and the tag pipeline.
Shares Busulfan, Melphalan (including hepatic delivery system) and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Ifosfamide, Etoposide and the tag pipeline.